Clinical Trials Logo

Filter by:
NCT ID: NCT03667066 Completed - Clinical trials for Platelet Dysfunction

Prevalence of clOpidogrel "resIstaNce" in a Selected Population of Patients Undergoing Elective Percutaneous Coronary Intervention at a Tertiary Cardiovascular Center in Trinidad

POINT Pilot
Start date: September 1, 2017
Phase:
Study type: Observational

The aim of this study was to determine the prevalence of clopidogrel resistance among a selected group of patients undergoing elective percutaneous coronary intervention and to observe whether there was any south-Asian (Indo-Trinidadian) predilection for HPR considering the well-established epidemiologic trends for accelerated CAD within this subgroup.

NCT ID: NCT03603249 Active, not recruiting - Clinical trials for Platelet Dysfunction Due to Drugs

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

TRACER
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

Hypothesis: Trimetazidine improves Clopidogrel response in patients. • The investigators postulate that the inhibition of platelet aggregation in response to Clopidogrel may be accentuated by Trimetazidine, i.e. Trimetazidine enhances Clopidogrel response. Null Hypothesis: There is no difference in Clopidogrel response in patients with stable coronary artery disease with adjunctive Trimetazidine.

NCT ID: NCT03258723 Not yet recruiting - Diabetes Clinical Trials

Diabetes Prevention With Lifestyle Intervention and Metformin Escalation

LIME
Start date: June 30, 2018
Phase: Phase 4
Study type: Interventional

Specific Aim: Implement an evidence-based diabetes prevention pragmatic trial for high risk pre-diabetic individuals of Caribbean-descent to reduce the incidence of diabetes. Hypothesis: This study seeks to test the hypothesis that implementation of a lifestyle intervention, with escalation to Metformin therapy will lower the incidence of diabetes among the highest risk pre-diabetic individuals of Caribbean-descent.

NCT ID: NCT02979938 Completed - Zika Virus Clinical Trials

Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection

Start date: July 2016
Phase:
Study type: Observational

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.

NCT ID: NCT02587806 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI).

NCT ID: NCT02587715 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT02418351 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI).

NCT ID: NCT02418325 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT01994811 Recruiting - Diabetes Clinical Trials

Eastern Caribbean Health Outcomes Research Network (ECHORN)

ECHORN
Start date: April 2013
Phase: N/A
Study type: Observational

The Eastern Caribbean Health Outcomes Research Network (ECHORN) is a collaborative research study that examines the lifestyles, eating habits, and health behaviors associated with cancer, diabetes and heart disease in adult men and women living in the Eastern Caribbean.

NCT ID: NCT01581944 Completed - Fibroids Clinical Trials

Gonadotropin-releasing Hormone Agonist Prior to Myomectomy

Start date: January 2008
Phase: Phase 3
Study type: Interventional

Fibroids are common in the West Indian population (30-40% of reproductive women).Fibroids are benign growth in the womb or uterus and in order to preserve the fertility of women they, require an operation called myomectomy or shelling out of the fibroid. This procedure can be associated with large blood loss. In current practice some obstetricians use a gonadotropin releasing hormone agonist prior to the operation to reduce blood loss. Gonadotropin releasing hormone agonist is used in current gynaecological practice to treat women with heavy periods. In this study the investigators randomised women to either 2 or 3 doses of the gonadotropin agonist prior to their operation and no treatment. The intraoperative blood loss was measured. The study hypothesis: To determine whether administration of gonadotropin releasing hormone agonist prior to myomectomy reduces intraoperative blood loss.